Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
Three drug-pricing controls emerge in U.S. market
Aetna, Apps, August 2018, Biosimilars, CVS Health, Department of Health and Human Services (HHS), Drug Pricing, DTC, Express Scripts Holding, FDA/Regulatory, Formularies, Issue Archives, Medicare, Medicare Part D, Sales & Marketing, Trump Administration, UnitedHealth GroupAs drug prices fall under increased scrutiny, payers and regulators are targeting some key initiatives that could change the dynamic of pharmacy benefit management over the next 12 months. These emerging trends point to potentially rougher terrain for drugmakers looking to increase market share as payers take a more active role in enforcing formularies.